(S1 (S (S (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (JJ nuclear) (NN insulin) (NN receptor) (NN substrate-2)) (CC and) (NP (NN NF-kappaB)))) (PP (IN in) (NP (NN IGF-1)))) (VP (VBZ induces) (NP (NN response)) (PP (IN in) (NP (NN breast) (NN cancer) (NNS cells))))) (. .)))
(S1 (S (S (PP (IN Despite) (NP (NP (JJ significant) (NN homology)) (PP (IN between) (NP (NP (NN IRS-1)) (CC and) (NP (NN IRS-2)))))) (, ,) (NP (JJ recent) (NNS studies)) (VP (VBP have) (VP (VBN revealed) (NP (NP (JJ distinct) (NNS functions)) (PP (IN for) (NP (DT these) (NN adaptor) (NNS proteins))) (PP (IN in) (S (VP (VBG regulating) (NP (NN breast) (NN cancer) (NN progression))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Thus) (RB far)) (, ,) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NNS studies)) (PP (IN on) (NP (NN breast) (NN cancer)))))) (VP (VBP have) (VP (VBN focused) (PP (IN upon) (NP (NN IRS-1)))))) (, ,) (NP (NP (DT the) (JJ biological) (NN pattern)) (PP (IN of) (NP (NN IRS-2)))) (VP (VBZ is) (VP (VBN limited)))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (IN that) (S (S (NP (NP (NN depletion)) (PP (IN of) (NP (JJ endogenous) (NN IRS-2))) (PP (IN by) (NP (JJ antisense) (NNS strategies)))) (VP (VP (VBD impaired) (NP (NN cell) (NN proliferation)) (PP (IN after) (NP (NN serum) (NN withdrawal)))) (, ,) (VP (VBD blunted) (NP (NN PI3K/Akt))))) (CC and) (S (NP (NP (NN NF-kappaB) (NN activation)) (PP (IN in) (NP (NN IGF-1)))) (VP (VBD induced) (NP (NP (NN response)) (PP (IN in) (NP (NN MCF-7) (CC and) (NN BT-20) (NN breast) (NN cancer) (NNS cells)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN IGF-1)) (VP (VBP promote) (NP (NP (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NP (NN IRS-2)) (CC and) (NP (NN NF-kappaB))))) (PP (IN in) (NP (NP (NN MCF-7)) (CC and) (NP (NN BT-20) (NNS cells)))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Nuclear) (NN IRS-2) (NN interaction)) (PP (IN with) (NP (NN NF-kappaB-p65)))) (CC and) (NP (NP (NN PI3K) (NN binding) (NN tyrosine) (NNS residues)) (PP (IN of) (NP (NN IRS-2))))) (VP (VBP are) (ADJP (JJ crucial) (PP (IN for) (NP (DT the) (NN NF-kappaB) (NNS activities)))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (JJ nuclear) (NN IRS-2)) (VP (VBZ is) (VP (VBN recruited) (PP (PP (TO to) (NP (DT the) (NN cyclin) (NN D1) (NN promoter))) (CC both) (PP (IN in) (NP (NN MCF-7) (CC and) (NN BT-20) (NNS cells))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ selective) (NN inhibition)) (PP (IN of) (NP (NN NF-kappaB-65)))) (VP (VBD abolished) (NP (NP (DT the) (NN occupancy)) (PP (IN of) (NP (NN IRS-2))) (PP (TO to) (NP (DT the) (NP (NN cyclin) (NN D1)) (NNS promoters)))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN IRS-2)) (VP (VBZ plays) (NP (DT a) (JJ significant) (NN role)) (PP (IN by) (S (VP (VBG activating) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (NP (NN NF-kappaB)) (PP (IN via) (NP (NP (NN PI3K/Akt) (NN pathway)) (SBAR (IN in) (S (NP (NP (NP (JJ IGF-1-induced) (NNS responses)) (PP (IN in) (NP (NN breast) (NN cancer) (NNS cells)))) (CC and) (NP (NP (DT the) (NN crosstalk)) (PP (IN between) (NP (NP (JJ nuclear) (NN IRS-2)) (CC and) (NP (NN NF-kappaB)))))) (VP (MD might) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ transcriptional) (NN progression)) (PP (IN of) (NP (DT the) (NN breast) (NN cancer) (NNS cells)))))))))))))))))))) (. .)))
